β-微精氨酸蛋白而非 CRISP3 在卵巢癌中表达降低，并与生存相关。

The expression of β-microseminoprotein but not CRISP3 is reduced in ovarian cancer and correlates to survival.

机构信息

Department of Obstetrics and Gynaecology, University Hospital SUS, Malmö, Sweden.

出版信息

Anticancer Res. 2012 Sep;32(9):3993-9.

Abstract

BACKGROUND

β-Microseminoprotein (MSMB) is an abundant protein in seminal plasma. Most of it is present as a free protein but a small part is bound to cysteine-rich secretory protein 3 (CRISP3) as a non-covalent complex. Even though their physiological function is unknown, both MSMB and CRISP3 have been ascribed roles in prostate carcinogenesis. Thus, several recent experimental studies indicate a tumor-suppressor role for MSMB. The present study was undertaken in order to evaluate, for the first time, the expression of MSMB and CRISP3 in ovaries and in ovarian tumors and to determine if their expression might indicate a role in ovarian tumor development.

MATERIALS AND METHODS

Biopsies from prospectively collected samples from ovaries and benign, borderline and invasive ovarian tumors were analyzed for expression of MSMB and CRISP3 by immunohistochemistry. In patients with ovarian cancer the expression was compared to survival.

RESULTS

Both MSMB and CRISP3 were strongly stained in ovarian epithelial cells and weakly stained in the stroma. In ovarian blood vessels, CRISP3 exhibited strong to medium staining, while MSMB was only weakly expressed. In benign and borderline tumors the staining pattern was similar to the one observed in the ovaries. In invasive neoplasms, the expression of MSMB in the tumor cells was significantly reduced. In univariate analysis, decreased expression of MSMB correlated to reduced survival. No correlation was found with stage, the strongest prognostic indicator for ovarian cancer, which supports an independent role of MSMB in ovarian carcinogenesis. For CRISP3, a staining pattern comparable to that for MSMB was observed in all groups, except the fact that decreased expression was not observed in invasive tumor cells.

CONCLUSION

MSMB and CRISP3 were widely distributed in ovaries and in ovarian tumors; the expression of MSMB fits well with a tumor-suppressor function in ovarian carcinogenesis.

摘要

背景

β-微精蛋白（MSMB）是精液中丰富的蛋白质。它的大部分以游离蛋白的形式存在，但一小部分与富含半胱氨酸的分泌蛋白 3（CRISP3）以非共价复合物的形式结合。尽管它们的生理功能尚不清楚，但 MSMB 和 CRISP3 都被认为在前列腺癌的发生中起作用。因此，最近的一些实验研究表明 MSMB 具有肿瘤抑制作用。本研究旨在首次评估 MSMB 和 CRISP3 在卵巢和卵巢肿瘤中的表达，并确定其表达是否可能表明其在卵巢肿瘤发展中的作用。

材料和方法

通过免疫组织化学分析前瞻性收集的卵巢和良性、交界性和侵袭性卵巢肿瘤组织样本中的 MSMB 和 CRISP3 表达。在卵巢癌患者中，将表达与生存进行比较。

结果

MSMB 和 CRISP3 在卵巢上皮细胞中均强烈染色，在基质中弱染色。在卵巢血管中，CRISP3 表现为强至中等染色，而 MSMB 仅弱表达。在良性和交界性肿瘤中，染色模式与在卵巢中观察到的相似。在侵袭性肿瘤中，肿瘤细胞中 MSMB 的表达显著降低。单因素分析显示，MSMB 表达降低与生存时间缩短相关。与卵巢癌最强的预后指标——分期无关，这支持 MSMB 在卵巢癌发生中的独立作用。对于 CRISP3，除在侵袭性肿瘤细胞中未观察到表达降低外，在所有组中观察到与 MSMB 相似的染色模式。